Inhibrx is a biotherapeutics discovery and development company, with an extensive internally developed pipeline. Active programs are focused on cancer, inflammatory and metabolic diseases. Inhibrx’s pipeline spans first-in-class to best-in-class therapeutics.

Inhibrx’s programs are based on comprehensive target discovery and selection expertise coupled to the creative implementation of multiple antibody and biologic development strategies for therapeutic lead generation, selection and optimization.

02-01-2011 - Inhibrx names John C. Reed, MD, PhD, Stephen Howell, MD, PhD, and Rand Mulford to Advisory Board.

10-24-2011 - ProBioGen and Inhibrx Sign License Deal on GlymaxX® ADCC Technology for Therapeutic Antibody Development